Academic Collaborations

Mission

Academic Collaborations

Clinical Lab Accreditations

Dana Farber Cancer Institute - Boston, MA

Nuclea and Dana Farber Cancer Institute (DFCI) collaborate in several areas of research in the oncology field.

The collaboration involves the application of both conventional and emerging molecular cytogenetic techniques for the analysis of genomic changes associated with disease. It is expected that the study of these genetic alterations will inform prognoses and facilitate implementation of targeted therapies. The collaboration involves novel application of molecular cytogenetic technologies specifically to the study of prostate and other cancers. Genomic signatures identified in tumors and examined through these technologies may constitute biomarkers for the disease, and lead to the development and implementation of novel diagnostic assays for the diagnosis and/or prognosis of cancer.

Nuclea provides philanthropic support to the Jimmy Fund, an organization that supports cancer research and care at Dana Farber. Nuclea makes frequent donations to the Jimmy Fund and sponsors fund-raising events to raise money for cancer research. Nuclea was recently elected to the Benacerraf Society 2008 for continued unwavering support for oncological research at the Dana Farber Cancer Institute.

Johns Hopkins School of Medicine – Baltimore, MD

Nuclea and Johns Hopkins School of Medicine (JHU) collaborate in research in the oncology field. One collaboration utilizes Nuclea's and JHU's tissue microarray (TMA) technology to investigate gene and protein expression as well as genomic structural changes, gene copy number and chromosomal rearrangements in various types of cancer.

Another collaboration between Nuclea and JHU involves research into DNA methylation changes in cancer utilizing JHU's technology which can survey, with extremely high resolution, all of the DNA methylation changes across the entire human genome in normal and cancer cells.

Clark University - Worcester, MA

Nuclea and Clark University collaborate in the area of inflammation research. The research is focused on developing cell lines and animal models for bioassays of lung fibrosis and other models of inflammation, including asthma, emphysema, and chronic obstructive pulmonary disease, as well as the discovery of biomarkers for early detection of inflammatory disorders that would allow for effective therapeutic interventions.

Another collaboration between Nuclea and Clark involves investigating the inactivation sites of certain mechanism-based inhibitors, and developing new selective inhibitors of lysyl oxidase and the lysyl oxidase-like enzymes.

[  back to top  ]